Major histocompatibility complex class I and II antigen presentation (MHC-I and MHC-II antigen presentation)

The term "Tumor antigen presentation via major histocompatibility complex class I and II molecules" refers to the biological process by which **tumor-derived antigens** are processed inside cells and displayed on the cell surface bound to either **MHC class I** or **MHC class II molecules**. This is not a single molecular target but rather an essential immunological pathway. **MHC class I molecules** present peptides derived from proteins synthesized within the cell (endogenous antigens), including mutated proteins from cancer cells, to CD8+ cytotoxic T lymphocytes. This allows the immune system to recognize and eliminate abnormal cells such as tumor cells[1][2][6]. Many cancers evade immune detection by downregulating components of this pathway, leading to resistance against T-cell-based immunotherapies[2][5]. **MHC class II molecules**, in contrast, present peptides derived from extracellular sources (exogenous antigens) that have been internalized by professional antigen-presenting cells such as dendritic cells, macrophages, and B-cells. These complexes activate CD4+ helper T-cells which coordinate broader aspects of anti-tumor immunity[1][3][6]. Because this entry describes a process rather than a discrete protein target (such as an enzyme or receptor), it is not considered a canonical therapeutic target itself but is central to many cancer immunotherapy strategies aiming to enhance tumor visibility to the immune system. Key points about this process include: - **Loss or dysfunction in these pathways enables tumors to escape immune surveillance**, making restoration of effective antigen presentation an important goal in cancer therapy[2]. - Drugs do not directly bind "antigen presentation" itself; instead, therapies may upregulate expression/function of these pathways indirectly. - The presence/absence of functional MHC-I on tumor cells can serve as both a biomarker for patient selection/response prediction and an indicator for potential resistance mechanisms against certain immunotherapies[2].

Other names

Antigen presentation via MHCTumor antigen presentation via major histocompatibility complexMHC-mediated tumor antigen display

Enhancement or inhibition of immune recognition by modulating peptide loading or expression of MHC molecules (for immunotherapies)